UNSPSC 51162700: Decongestants, expectorants, and mucolytics

This classification denotes drugs that a) treat nasal passage inflammation, substances called decongestants; and/or b) increase mucous excretion, substances called expectorants and/or mucolytics, thus the term DECONGESTANTS, EXPECTORANTS, AND MUCOLYTICS.

UNSPSC 51162700 Decongestants, expectorants, and mucolytics is a Class code whose scope in recent state and local solicitations diverges sharply from its nominal taxonomy name. The two recent opportunities tagged to this code actually solicit parenteral pharmaceutical products and naloxone — neither decongestants nor expectorants. The Washington State Department of Corrections issued RFQ RFQQK13020 in September 2026 for parenteral nutrition solutions (TPN and PPN), intravenous solutions, and parenteral products including controlled substances to supply eight correctional facilities across three regions, with response due October 7, 2026 and contract performance running November 2026 through June 2030. The code shows activity from correctional healthcare buyers and public health agencies, with set-aside goals for small, minority-owned, women-owned, and veteran-owned businesses available in the Washington procurement; Seminole County, Florida's parallel naloxone procurement (IFB 60459723LAS) called for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with one-year renewal option.

The recent opportunities span Washington and Florida, with the Washington solicitation representing the more substantial and recent activity under this code number. The mismatch between the code's decongestant-and-expectorant label and the parenteral-products and naloxone procurement actually posted suggests either misclassification by the issuing jurisdictions or a data-taxonomy drift in how state and local offices tag pharmaceutical and medical-supply solicitations. Bidders pursuing this code should treat the posted opportunities—parenteral compounding and delivery for corrections healthcare, and public health naloxone procurement—as the decision-relevant market signal rather than the abstract code name, and monitor whether future postings under this number continue to diverge from traditional respiratory-medication categories.